Real World Study with Benralizumab in Severe Asthma in Switzerland - BEEPS

Study identifier:D3250R00048

ClinicalTrials.gov identifier:NCT03907137

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Utilisation of Benralizumab in the Clinical Practise in Severe Eosinophilic Asthma Patients in Switzerland

Medical condition

Severe Eosinophilic Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

79

Study type

Observational

Age

18 Years +

Date

Study Start Date: 21 Jan 2019
Estimated Primary Completion Date: 31 Dec 2022
Estimated Study Completion Date: 31 Dec 2022

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Oct 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria